Day 5 Embryo Transfer vs Day 3: How Timing Is Chosen
Key Takeaways
A blastocyst is an embryo that has reached a more advanced stage, usually on day 5 or 6. Transfer on day 5 often helps selection when several embryos are available, but day 3 can still make sense when numbers are limited. Freeze-all and PGT also change the calendar.
Key evidence: Cochrane 2026: Blastocyst-stage versus cleavage-stage embryo transfer ASRM 2018: Blastocyst culture and transfer
Day 5 embryo transfer — not a fixed rule
A day 5 embryo (blastocyst) has usually formed an inner cell mass and trophectoderm. Waiting to day 5 or day 6 can help the lab see which embryos keep developing. That helps most when several embryos are available.
A live birth means a baby born after the pregnancy. The current Cochrane review finds that fresh blastocyst transfer probably raises the chance of live birth mainly in patients with a good outlook for pregnancy. Counting later frozen transfers from the same egg collection (cumulative live birth), the gain within about 12 months may be small, but confidence is low and studies vary. Extended culture can also raise the chance that no embryo is ready to transfer.
Earlier transfer can still be right when the group of embryos is small, or when longer culture adds little for that cycle. Transfer stage is only one of the factors behind IVF success rates and how they are calculated, not a single calendar rule.
Evidence box: Cochrane 2026 in plain numbers
The 2026 Cochrane update (searches to October 2024; 36 trials) reports that fresh blastocyst transfer probably increases live birth versus cleavage-stage transfer (moderate certainty). Cumulative live birth within 12 months may increase slightly (low certainty), with high variation between trials. Cumulative preterm birth is probably higher with blastocyst strategies. Failure to transfer any embryo may be higher after planned blastocyst culture; fewer surplus embryos may be frozen. Most participants had a good prognosis, so findings should not be generalised to poorer-prognosis cycles.
Common transfer timing options
Cleavage stage (day 2 or day 3)
At this stage, embryos usually contain about 4 to 8 cells. Day 2–3 transfer is less common than it once was. It still has a role when only a few embryos are available, or when prolonged culture is unlikely to add useful selection.
Blastocyst stage (day 5 or day 6)
Embryos that reach the blastocyst stage have passed extra developmental checkpoints. Day 5 embryo transfer is common in modern IVF when several embryos are available and the laboratory can support extended culture reliably.
Some embryos become an optimal blastocyst only on day 6. That does not mean day 5 culture “failed.” It is still a blastocyst pathway.
A pooled analysis of observational studies (not randomised trials) found higher rates of clinical pregnancy and live birth after day 5 than day 6 transfers. A clinical pregnancy is one confirmed on ultrasound. The gap appeared in fresh cycles and in cycles using vitrified (flash-frozen) embryos. Embryo quality and the transfer setting still matter (Bourdon et al., 2019). Slower blastocysts may miss the implantation window in a fresh cycle; freezing and transferring later can partly reduce that mismatch (ESHRE/ALPHA Istanbul Consensus update, 2025).
| Stage | Typical picture | Often chosen when… |
|---|---|---|
| Day 3 | Cleavage (≈6–8 cells) | Limited embryo number; individualised plan |
| Day 5 / 6 | Blastocyst | Several good embryos; selection value; PGT planned |
What influences the timing?
- Embryo development and quality — when several embryos progress well, waiting to day 5 can refine selection.
- Previous IVF history and age — prior patterns may favour earlier transfer, blastocyst culture, or freeze-all (freezing every embryo for a later transfer).
- Embryo number — with many embryos, extra days in culture carry less risk. With very few, waiting to day 5 may leave nothing to transfer.
- Laboratory conditions — blastocyst culture works only as well as the lab that supports it.
- Endometrium and cycle planning — sometimes the better move is a frozen transfer in a cycle where the lining is prepared with evidence-based methods, not an earlier or later fresh transfer. Practical steps are in frozen-embryo endometrial preparation.
- Genetic testing — PGT generally needs blastocyst-stage biopsy.
Cell division rate, fragmentation, and later expansion or hatching are watched daily. Morphology grades (for example 4AA or 3BB) describe appearance at a moment in time — see IVF embryo grading.
Fresh day 5 transfer versus freeze-all
A day 5 embryo can be transferred in the same stimulated cycle or frozen for later. Freeze-all may be preferred when hormone levels, lining, OHSS risk, or PGT results argue for waiting. ASRM OHSS guidance and the ESHRE ovarian stimulation update (2025) support freeze-all strategies when OHSS risk is high. Neither path is universally “better”; the choice depends on the clinical context.
After transfer, practical care matters more than rituals — what to do after embryo transfer.
Clinical Note
Dr. Aksoy’s approach: Day 5 culture is mainly useful for refining selection when several good embryos are available. When embryo numbers are limited, day 3 transfer remains an option to discuss to reduce the risk of having no embryo available after extended culture. The decision also considers the endometrium, laboratory conditions, PGT, and the rest of the treatment plan.
Frequently Asked Questions for Dr. Aksoy
With only one or two day-3 embryos, do you transfer on day 3 or continue culture to day 5?
When we have only one or two embryos, I do not think we must keep them in culture until day 5. I weigh the woman’s age, previous treatment results, cell number on day 3, how similar the cells look, fragmentation, and our laboratory’s blastocyst development results. In older patients with few embryos that are developing appropriately, I may prefer day-3 transfer. If development looks good and laboratory conditions are suitable, culture to day 5 is also a reasonable option.
One point matters: failing to reach day 5 in the lab does not mean the same embryo would have produced a pregnancy if transferred on day 3. Blastocyst culture can help us select better; it does not increase an embryo’s biological potential. That is why I do not use the same approach for every patient.
If the best embryo is a day-6 blastocyst, how do you assess it? Are freeze and transfer criteria different from day 5?
I do not treat a day-6 blastocyst as a bad result. Day-5 blastocysts have higher pregnancy and live-birth rates on average, yet we also obtain healthy pregnancies with embryos that reach the blastocyst stage on day 6. Besides the day of development, I assess the inner cell mass, trophectoderm quality, and degree of expansion. I do not discard day-6 embryos only because they are one day slower; if they meet suitable morphological criteria for transfer or freezing, I keep them.
For day-6 blastocysts I usually prefer frozen embryo transfer, which can reduce possible asynchrony between embryo development and the endometrial implantation window. I tell patients the embryo developed one day later — not that there is no chance of pregnancy.
If the endometrium and hormones look normal, do you prefer fresh day-5 transfer or freeze-all?
When the lining and hormone values look suitable, I do not think every patient needs embryos frozen. Fresh day-5 transfer is a perfectly good option for many patients. What changes my decision most are the progesterone level on the trigger day, how the ovaries responded to stimulation, OHSS risk, and whether the endometrium is truly ready for transfer. If progesterone rose early, OHSS risk is high because of an exaggerated response, or I find something such as fluid in the cavity that could harm implantation, I prefer to freeze and transfer in a later cycle.
If hormones are suitable, the lining is adequate, and OHSS risk is low, I do not abandon fresh transfer only because frozen transfer is thought to be more successful. Applying freeze-all to everyone has not been shown to raise live-birth rates. What matters is not insisting on fresh or frozen, but choosing the right timing for that patient.
Sources
- Glujovsky D, Cornelisse S, Blake D, Quinteiro Retamar AM, Alvarez Sedo CR, Ciapponi A. “Blastocyst-stage versus cleavage-stage embryo transfer in assisted reproductive technology.” Cochrane Database Syst Rev 2026;1(1):CD002118.pub7. Cochrane | DOI
- Practice Committee of the American Society for Reproductive Medicine. “Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion” (2018). Fertil Steril 110:1246–52. ASRM
- Hsueh YW et al. “Finding of the optimal preparation and timing of endometrium in frozen-thawed embryo transfer: a literature review of clinical evidence.” Front Endocrinol (Lausanne) 2023;14:1250847. PubMed
- American Society for Reproductive Medicine. “Comprehensive guidance for human embryology, andrology, and endocrinology laboratories: management and operations: a committee opinion.” Fertil Steril 2022;117:1183–202. ASRM
- Practice Committee of the American Society for Reproductive Medicine. “Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline.” Fertil Steril 2024;121:230–45. ASRM
- Bourdon M et al. “Day 5 versus Day 6 blastocyst transfers: a systematic review and meta-analysis of clinical outcomes.” Hum Reprod 2019;34:1948–64. PubMed | DOI
- ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. “The Istanbul Consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment.” Hum Reprod 2025;40:989–1035. DOI | ESHRE page
- ESHRE Guideline Group on Ovarian Stimulation. “ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025.” Hum Reprod 2026;41:498–514. DOI | ESHRE guideline
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.